本帖最后由 老马 于 2012-1-13 21:20 编辑 ; K, j4 L! F; y, f5 |- @ z
1 R5 i& [1 {; ~) j2 |) u( D爱必妥和阿瓦斯丁的比较$ c. [: i0 j: a
8 S7 ^9 r6 ]+ y; R! `% K% T" ahttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
# V* `/ l. d, i# I8 B8 O8 `
+ P! N3 E' {' K/ I6 v
) I7 d0 g2 g: E! G" dhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/* a' @8 W. o! J, v1 J
==================================================
3 i. W% `# v. k9 j% a, JOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL); X# i1 j+ {6 p/ U) n; u: y' k5 A3 y, k
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.+ _/ n$ P8 @6 i& e8 d% M6 O
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
& N4 q5 G6 ~- ]; u0 b7 f
|